Q-omics provides the consensus-scored LINC01563 profile across patient tissues and cancer cell-line models. LINC01563 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01563 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, LINC01563 RNA expression shows 11,503 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where LINC01563 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01563 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01563 survival associations across molecular data types. LINC01563 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01563 RNA expression–survival associations across cancer types. High LINC01563 expression shows unfavorable associations in KIRP, COAD, LGG, ESCA and THYM, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01563 RNA expression.
This table summarizes LINC01563 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01563. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01563 shows lower tumor expression in KICH, KIRC, UCEC, COAD, PRAD and LUSC. The KICH box plot shows higher LINC01563 RNA expression in normal versus tumor tissue (log2 FC = −0.248, t-test p < 0.001).
This table shows molecular features associated with LINC01563 in patient tissues and cancer cell lines. In patient samples, LINC01563 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
